相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of imaging modality on clinical outcome in Hodgkin lymphoma in a resource constraint setting
Anu Korula et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study
Abi Vijenthira et al.
LANCET HAEMATOLOGY (2020)
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma
Deborah M. Stephens et al.
BLOOD (2019)
Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease
Ann S. LaCasce
HEMATOLOGICAL ONCOLOGY (2019)
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study
Rene-Olivier Casasnovas et al.
LANCET ONCOLOGY (2019)
Survivors' perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group
Stefanie Kreissl et al.
LEUKEMIA & LYMPHOMA (2019)
Transplant strategies in relapsed/refractory Hodgkin lymphoma
Gunjan L. Shah et al.
BLOOD (2018)
Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial
Andrea Gallamini et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
J. M. Connors et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
Craig H. Moskowitz et al.
BLOOD (2018)
Impact of Imaging Modality on Clinical Outcome in Hodgkin Lymphoma in a Resource Constrained Setting
Anu Korula et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
Alex F. Herrera et al.
BLOOD (2018)
Treatment-Resistant Hodgkin Lymphoma Defining the Role of Autologous Transplantation
Kristie A. Blum
CANCER JOURNAL (2018)
RESPONSE-ADJUSTED THERAPY FOR ADVANCED HODGKIN LYMPHOMA (RATHL) TRIAL: LONGER FOLLOW UP CONFIRMS EFFICACY OF DE-ESCALATION AFTER a NEGATIVE INTERIM PET SCAN (CRUK/07/033).
J. Trotman et al.
HEMATOLOGICAL ONCOLOGY (2017)
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
Peter Borchmann et al.
LANCET (2017)
Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting
Toby A. Eyre et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma
P. J. Broeckelmann et al.
ANNALS OF ONCOLOGY (2017)
Core needle biopsies and surgical excision biopsies in the diagnosis of lymphoma-experience at the Lymph Node Registry Kiel
Alice Johl et al.
ANNALS OF HEMATOLOGY (2016)
Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial
Patrice Carde et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration
Karolin Behringer et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study
Pier Luigi Zinzani et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816
Oliver W. Press et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi
Francesco Merli et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group
Stefanie Kreissl et al.
LANCET ONCOLOGY (2016)
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma
Peter Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Treatment of advanced-stage Hodgkin lymphoma
Theodoros P. Vassilakopoulos et al.
SEMINARS IN HEMATOLOGY (2016)
Acute myeloid leukaemia: challenges and real world data from India
Chepsy Philip et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Assuring health coverage for all in India
Vikram Patel et al.
LANCET (2015)
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Craig H. Moskowitz et al.
LANCET (2015)
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
Alison J. Moskowitz et al.
LANCET ONCOLOGY (2015)
ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial
N. Mounier et al.
ANNALS OF ONCOLOGY (2014)
Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma
Graham P. Collins et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Guidelines for the first line management of classical Hodgkin lymphoma
George A. Follows et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12
Michael Crump et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
Craig H. Moskowitz et al.
BLOOD (2012)
The role of hematopoietic stem cell transplantation in the treatment of relapsed/refractory Hodgkin's lymphoma
Anna Sureda et al.
CURRENT OPINION IN ONCOLOGY (2012)
Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy
Raynier Devillier et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Insured yet vulnerable: out-of-pocket payments and India's poor
Renu Shahrawat et al.
HEALTH POLICY AND PLANNING (2012)
Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography/Computed Tomography-Staged Treatment-Naive Patients With Hodgkin Lymphoma
Tarec Christoffer El-Galaly et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
Andreas Engert et al.
LANCET (2012)
ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned
Simonetta Viviani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma
Alison J. Moskowitz et al.
BLOOD (2010)
18F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging
Gerard Moulin-Romsee et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Fertility preservation after chemotherapy for Hodgkin lymphoma
Marleen A. E. van der Kaaij et al.
HEMATOLOGICAL ONCOLOGY (2010)
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
Massimo Federico et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Risk-Adapted Salvage Treatment With Single or Tandem Autologous Stem-Cell Transplantation for First Relapse/Refractory Hodgkin's Lymphoma: Results of the Prospective Multicenter H96 Trial by the GELA/SFGM Study Group
Franck Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Ifosfamide, gemcitabine, and vinorelbine: a now induction regimen for refractory and relapsed Hodgkin's lymphoma
Armando Santoro et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: A randomized controlled trial
Marieke F. M. Gielissen et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse
A Sureda et al.
ANNALS OF ONCOLOGY (2005)
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:: a randomised trial
N Schmitz et al.
LANCET (2002)
Kairos in Aristotle's rhetoric
JL Kinneavy et al.
WRITTEN COMMUNICATION (2000)
分享论文
